Literature DB >> 2543286

Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations.

D E Low1, A McGeer, R Poon.   

Abstract

The in vitro activities of daptomycin, teicoplanin, and three other antimicrobial agents were determined against 105 strains of Staphylococcus haemolyticus and 92 strains of Staphylococcus epidermidis. The MICs for 90% of strains tested (MIC90s) of fusidic acid and rifampin were less than or equal to 0.25 microgram/ml. The MIC90s of daptomycin and vancomycin were less than or equal to 4 micrograms/ml. Teicoplanin had a comparable MIC90 of less than or equal to 4 micrograms/ml for isolates of S. epidermidis. However, MIC90s were 8 and 16 micrograms/ml for oxacillin-susceptible and oxacillin-resistant S. haemolyticus, respectively. Disk diffusion tests were evaluated for daptomycin and teicoplanin. Disks with 30 micrograms of teicoplanin performed satisfactorily when S. epidermidis was tested, but when S. haemolyticus was tested, there was a very major error rate of 10% and a minor error rate of 38%.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543286      PMCID: PMC172486          DOI: 10.1128/AAC.33.4.585

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

Review 1.  Microbiological properties of teicoplanin.

Authors:  D Greenwood
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

2.  Antibiotic susceptibility testing of Pseudomonas aeruginosa: selection of a control strain and criteria for magnesium and calcium content in media.

Authors:  L B Reller; F D Schoenknecht; M A Kenny; J C Sherris
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

3.  Speciation of coagulase-negative staphylococci in the clinical laboratory.

Authors:  P D Ellner; B Myrick
Journal:  Eur J Clin Microbiol       Date:  1982-04       Impact factor: 3.267

4.  Species identification and susceptibility to 17 antibiotics of coagulase-negative staphylococci isolated from clinical specimens.

Authors:  F J Marsik; S Brake
Journal:  J Clin Microbiol       Date:  1982-04       Impact factor: 5.948

5.  Clinical significance of coagulase-negative staphylococci.

Authors:  C M Sewell; J E Clarridge; E J Young; R K Guthrie
Journal:  J Clin Microbiol       Date:  1982-08       Impact factor: 5.948

6.  Species identification of coagulase-negative staphylococcal isolates from blood cultures.

Authors:  R H Eng; C Wang; A Person; T E Kiehn; D Armstrong
Journal:  J Clin Microbiol       Date:  1982-03       Impact factor: 5.948

7.  Identification of coagulase-negative staphylococci with the API staph system.

Authors:  C G Gemmell; J E Dawson
Journal:  J Clin Microbiol       Date:  1982-11       Impact factor: 5.948

8.  In vitro activity of teichomycin and vancomycin alone and in combination with rifampin.

Authors:  P E Varaldo; E Debbia; G C Schito
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

9.  In vitro activity of teichomycin A 2 in comparison with penicillin and vancomycin against gram-positive cocci.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1982-10       Impact factor: 3.267

10.  An analysis of error rates for disc agar-diffusion testing of Pseudomonas aeruginosa versus aminoglycosides.

Authors:  B F Woolfrey; J M Fox; C O Quall
Journal:  Am J Clin Pathol       Date:  1981-04       Impact factor: 2.493

View more
  11 in total

1.  In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin.

Authors:  F Brunet; G Vedel; F Dreyfus; J F Vaxelaire; T Giraud; B Schremmer; J F Monsallier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

3.  In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.

Authors:  R S Schwalbe; A C McIntosh; S Qaiyumi; J A Johnson; R J Johnson; K M Furness; W J Holloway; L Steele-Moore
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

4.  Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci.

Authors:  E A Gorzynski; D Amsterdam; T R Beam; C Rotstein
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

5.  Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.

Authors:  D R Snydman; N V Jacobus; L A McDermott; J R Lonks; J M Boyce
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

6.  Use of multivariate analysis to compare antimicrobial agents on the basis of in vitro activity data.

Authors:  J M Hernández; P Conforti
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

7.  In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin.

Authors:  K C Lamp; M J Rybak; E M Bailey; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

8.  Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium.

Authors:  K C Lamp; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

9.  Prevalence of antibiotic resistance among clinical isolates of methicillin-resistant staphylococci.

Authors:  M F Tripodi; V Attanasio; L E Adinolfi; A Florio; P Cione; S Cuccurullo; R Utili; G Ruggiero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-02       Impact factor: 3.267

Review 10.  Update on clinical significance of coagulase-negative staphylococci.

Authors:  W E Kloos; T L Bannerman
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.